Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group - 11/11/21
, Antoine Meyer a, 1, David Malka b, Margarida Matias b, Thierry De Baere c, Pascal Hammel d, Antonio Sa Cunha e, Angelica Lucchese e, David Fuks f, Romain Coriat g, Claire Gallois h, Yann Touchefeu i, Marianne Maillet j, Isabelle Trouilloud k, Pierre Rompteaux l, Franck Carbonnel a, Emilie Soularue mBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | In highly selected patients, local treatment of metastases from PDAC is associated with prolonged survival. |
• | Factors associated with shorter OS were liver metastases, N2 status and synchronous metastases. |
• | The rate of severe complications was low. |
Abstract |
Objective |
This study reports the efficacy and safety of local treatment of metastases of pancreatic ductal adenocarcinoma (PDAC), with a curative intent.
Methods |
We retrospectively included patients with histologically proven PDAC, who underwent a local treatment for metastases between January 1, 2000 and December 31, 2017, from 11 French hospitals. Complications of local treatment were reported. Univariate Cox models were performed to identify prognosis factors associated with overall survival (OS) and disease-free survival (DFS).
Results |
We included 52 patients treated for 68 metastases; 33 (64%) of whom had metachronous metastases. Metastatic sites treated were: 39 (57%) hepatic, 18 (27%) pulmonary and 11 (16%) others. Metastases treatments were: 45 (66%) surgery, 9 (13%) radiofrequency and 14 (21%) other procedures. The rates of severe complications and mortality were respectively 10% and 4%. The median OS and DFS after local treatment were 36.5 months and 12.7 months, respectively. Prognosis factors associated with a shorter OS were: liver metastases when compared with lung metastases (HR 4.04; 95%CI: 1.18−13.81), N2 status of primary pancreatic tumor when compared to N0–N1 (HR 9.43; 95%CI: 2.44−36.36) and synchronous metastases when compared to metachronous metastases (HR 2.34; 95%CI: 1.05−5.23). N2 status of primary pancreatic tumor was associated with a shorter DFS when compared to N0-N1 (HR 2.82; 95%CI: 1.05–7.58).
Conclusion |
In this series of highly selected patients, local treatment of metastases from PDAC is associated with prolonged survival. The rate of severe complications was low. Factors associated with shorter OS were liver metastases, N2 status and synchronous metastases.
Le texte complet de cet article est disponible en PDF.Keywords : Local treatment, Pancreatic cancer, Metastases, Curative intent, Surgery, Radiotherapy
Plan
Vol 45 - N° 6
Article 101607- novembre 2021 Retour au numéro
Article précédent
- Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study
- Claire Gallois, Camille Bourillon, Edouard Auclin, Pascal Artru, Astrid Lièvre, Thierry Lecomte, Christophe Locher, Lysiane Marthey, Roger Faroux, Simon Pernot, Maximilien Barret, Julien Taieb
- Prospective evaluation of third-generation small bowel capsule endoscopy videos by independent readers demonstrates poor reproducibility of cleanliness classifications
- Xavier Dray, Guy Houist, Jean-Philippe Le Mouel, Jean-Christophe Saurin, Geoffroy Vanbiervliet, Chloé Leandri, Gabriel Rahmi, Clotilde Duburque, Julien Kirchgesner, Romain Leenhardt, Franck Cholet, Lucille Quénéhervé
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?